FDA grants priority review for potential bronchiectasis treatment
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...
Insmed Gets Speedy FDA Review of Brensocatib for Bronchiectasis
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...
Medscape11d
Diagnosis of Allergic Bronchopulmonary Aspergillosis: A Case-Based Approach
Allergic bronchopulmonary aspergillosis is a pulmonary disease occurring in patients with asthma or cystic ... B: Bronchiectasis; CPF: Chronic pleuropulmonary fibrosis; HAM: High attenuation ...
Insmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.
While bronchiectasis occurs in patients with cystic fibrosis, Insmed tested brensocatib in patients with the condition who ...